Trial Profile
Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; CMB 305 (Primary) ; Cyclophosphamide (Primary) ; LV 305 (Primary) ; T lymphocyte cell therapies (Primary)
- Indications Liposarcoma; Myxoid liposarcoma; Sarcoma; Synovial sarcoma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2023 Status changed from active, no longer recruiting to completed.
- 25 Feb 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.
- 03 May 2021 Number of treatment arms is decreased from 3 to 2, by removing experimental cohort 2 arm.